GH vs. CC
GH (Guardant Health, Inc.) and CC (The Chemours Company) are both stocks. GH operates in Diagnostics & Research (Healthcare), while CC operates in Specialty Chemicals (Basic Materials). Over the past 5 years, GH returned 6.67%/yr vs -8.79%/yr for CC. At a 0.20 correlation, their price movements are largely independent.
Performance
GH vs. CC - Performance Comparison
Loading charts...
Returns By Period
The year-to-date returns for both stocks are quite close, with GH having a 55.08% return and CC slightly lower at 55.02%.
GH
- 1D
- -1.03%
- 1M
- 20.35%
- 6M
- 47.25%
- YTD
- 55.08%
- 1Y
- 215.22%
- 3Y*
- 60.49%
- 5Y*
- 6.67%
- 10Y*
- —
CC
- 1D
- 1.74%
- 1M
- -17.64%
- 6M
- 24.16%
- YTD
- 55.02%
- 1Y
- 33.97%
- 3Y*
- -19.24%
- 5Y*
- -8.79%
- 10Y*
- 10.91%
GH vs. CC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
GH Guardant Health, Inc. | 55.08% | 234.34% | 12.94% | -0.55% | -72.81% | -22.39% | 64.93% | 107.87% | 35.46% |
CC The Chemours Company | 55.02% | -27.57% | -44.01% | 6.53% | -5.99% | 39.85% | 45.61% | -32.54% | -31.68% |
Correlation
The correlation between GH and CC is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Oct 4, 2018 | 0.20 |
The correlation between GH and CC shifts across timeframes, from 0.08 (1 year) to 0.22 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
GH:
$21.00B
CC:
$2.72B
GH:
-$3.37
CC:
-$4.10
GH:
18.83
CC:
0.31
GH:
$1.08B
CC:
$5.82B
GH:
$701.01M
CC:
$878.00M
GH:
-$411.42M
CC:
$66.00M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GH vs. CC — Risk / Return Rank
GH
CC
GH vs. CC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Guardant Health, Inc. (GH) and The Chemours Company (CC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GH | CC | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.05 | ||
| Sortino ratioReturn per unit of downside risk | +3.01 | ||
| Omega ratioGain probability vs. loss probability | 1.52 | 1.14 | +0.38 |
| Calmar ratioReturn relative to maximum drawdown | 6.57 | 0.86 | +5.71 |
| Martin ratioReturn relative to average drawdown | 16.55 | 1.81 | +14.74 |
Loading charts...
Drawdowns
GH vs. CC - Drawdown Comparison
The maximum GH drawdown since its inception was -91.03%, which is greater than CC's maximum drawdown of -86.15%. Use the drawdown chart below to compare losses from any high point for GH and CC.
Loading charts...
Drawdown Indicators
| GH | CC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.03% | -86.15% | -4.88% |
Max Drawdown (1Y)Largest decline over 1 year | -32.98% | -39.79% | +6.81% |
Max Drawdown (3Y)Largest decline over 3 years | -59.79% | -73.44% | +13.65% |
Max Drawdown (5Y)Largest decline over 5 years | -87.84% | -76.42% | -11.42% |
Max Drawdown (10Y)Largest decline over 10 years | — | -86.15% | — |
Current DrawdownCurrent decline from peak | -11.56% | -56.43% | +44.87% |
Average DrawdownAverage peak-to-trough decline | -51.23% | -41.04% | -10.19% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.11% | 18.83% | -5.72% |
Volatility
GH vs. CC - Volatility Comparison
Guardant Health, Inc. (GH) has a higher volatility of 17.97% compared to The Chemours Company (CC) at 16.90%. This indicates that GH's price experiences larger fluctuations and is considered to be riskier than CC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GH | CC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.97% | 16.90% | +1.07% |
Volatility (6M)Calculated over the trailing 6-month period | 40.49% | 48.50% | -8.01% |
Volatility (1Y)Calculated over the trailing 1-year period | 60.61% | 63.96% | -3.35% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 68.06% | 55.97% | +12.09% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 68.30% | 56.62% | +11.68% |
Dividends
GH vs. CC - Dividend Comparison
GH has not paid dividends to shareholders, while CC's dividend yield for the trailing twelve months is around 1.93%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CC The Chemours Company | 1.93% | 4.35% | 5.92% | 3.17% | 3.27% | 2.98% | 4.03% | 5.53% | 2.98% | 0.24% | 0.54% | 10.82% |
GH Guardant Health, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
GH vs. CC - Financials Comparison
This section allows you to compare key financial metrics between Guardant Health, Inc. and The Chemours Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GH vs. CC - Profitability Comparison
GH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Guardant Health, Inc. reported a gross profit of 196.75M and revenue of 301.67M. Therefore, the gross margin over that period was 65.2%.
CC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, The Chemours Company reported a gross profit of 212.00M and revenue of 1.38B. Therefore, the gross margin over that period was 15.4%.
GH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Guardant Health, Inc. reported an operating income of -121.35M and revenue of 301.67M, resulting in an operating margin of -40.2%.
CC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, The Chemours Company reported an operating income of 39.00M and revenue of 1.38B, resulting in an operating margin of 2.8%.
GH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Guardant Health, Inc. reported a net income of -112.08M and revenue of 301.67M, resulting in a net margin of -37.2%.
CC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, The Chemours Company reported a net income of -29.00M and revenue of 1.38B, resulting in a net margin of -2.1%.
Frequently Asked Questions
GH and CC have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GH has higher volatility (17.97%) compared to CC (16.90%). In terms of maximum drawdown, GH dropped -91.03% vs CC's -86.15%.
GH currently has the higher Sharpe Ratio (3.58 vs 0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GH and CC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer